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A semi-automated luminescence 
based standard membrane feeding 
assay identifies novel small 
molecules that inhibit transmission 
of malaria parasites by mosquitoes
Martijn W. Vos1,*, Will J. R. Stone2,*, Karin M. Koolen1, Geert-Jan van Gemert2, Ben van 
Schaijk2, Didier Leroy3, Robert W. Sauerwein1,2, Teun Bousema2 & Koen J. Dechering1
Current first-line treatments for uncomplicated falciparum malaria rapidly clear the asexual stages of 
the parasite, but do not fully prevent parasite transmission by mosquitoes. The standard membrane 
feeding assay (SMFA) is the biological gold standard assessment of transmission reducing activity 
(TRA), but its throughput is limited by the need to determine mosquito infection status by dissection 
and microscopy. Here we present a novel dissection-free luminescence based SMFA format using a 
transgenic Plasmodium falciparum reporter parasite without resistance to known antimalarials and 
therefore unrestricted in its utility in compound screening. Analyses of sixty-five compounds from the 
Medicines for Malaria Venture validation and malaria boxes identified 37 compounds with high levels of 
TRA (>80%); different assay modes allowed discrimination between gametocytocidal and downstream 
modes of action. Comparison of SMFA data to published assay formats for predicting parasite infectivity 
indicated that individual in vitro screens show substantial numbers of false negatives. These results 
highlight the importance of the SMFA in the screening pipeline for transmission reducing compounds 
and present a rapid and objective method. In addition we present sixteen diverse chemical scaffolds 
from the malaria box that may serve as a starting point for further discovery and development of 
malaria transmission blocking drugs.
The introduction of Artemisinin combination therapy (ACT) as the first line treatment for malaria has contributed 
substantially to recent declines in child mortality across Africa1,2. ACT rapidly clear the Plasmodium life stages 
responsible for clinical disease but at the dose used to clear asexual blood stage parasites have only limited effect 
against mature gametocytes, the stage transmitted to mosquitoes3. Though immature gametocytes may be cleared 
shortly after their production4 resulting in reduced gametocyte burden and transmission potential5, current dosing 
regimens of ACT do not radically clear mature transmission stages and do not prevent transmission shortly after 
treatment6. Expanding efforts to achieve local malaria elimination and contain transmission in areas of emerging 
ACT resistance have stimulated interest in combining standard treatment with compounds active against mature 
gametocytes7 and have highlighted the need to screen new antimalarial drug candidates for their transmission 
reducing activity (TRA).
Currently the only available drug that radically prevents malaria transmission is primaquine8, but its wide-scale 
deployment is hampered by issues of safety and dosing9,10. Though the results of numerous ongoing trials give 
reason to expect wider scale use of single-low dose primaquine for reducing P. falciparum transmission, there is 
growing interest in identifying novel transmission reducing compounds7.
For screening new compounds, several assays determining gametocyte viability activity have been developed. 
These have been based on the expression of metabolic markers or reporter genes, or more recently on gametocyte 
1TropIQ Health Sciences, PO Box 9101, 6500 HB Nijmegen, The Netherlands. 2Department of Medical Microbiology, 
Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands. 3Medicines for Malaria Venture, 
20 Route de Pré-Bois, 1215 Geneva 15, Switzerland. *These authors contributed equally to this work. Correspondence 
and requests for materials should be addressed to K.J.D. (email: k.dechering@tropiq.nl)
received: 21 September 2015
accepted: 24 November 2015
Published: 21 December 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:18704 | DOI: 10.1038/srep18704
activation in vitro measured by the presence of female and male gametes11–13. Such assays are, however, not always 
predictive of blocking transmission of the parasite to the mosquito, and agents with putative TRA are best tested 
in the standard membrane feeding assay (SMFA). In the SMFA cultured gametocytes are mixed with blood and 
test compounds, and this mix is fed to laboratory reared mosquitoes to determine the effect of the compound on 
the parasites establishment in the mosquito. As the outcome of the SMFA is mosquito infection and the timing 
and duration of compound exposure is controlled, the assay is easily adapted to assess effects active at any stage 
of parasite development – from gametocyte inhibition, to inhibition of sporogony13,14. The SMFA has numerous 
pitfalls though, first among these being the need to dissect mosquitoes and count oocysts on the mosquito midgut 
by microscopy; a labour intensive and subjective task, which imposes significant limits on the assays scalability. 
We previously described the use of a parasite line expressing a fusion of the green fluorescent and firefly luciferase 
proteins (NF54HT-GFP-Luc) in a new SMFA format based on the measurement of luciferase activity in groups 
of homogenised individual or pooled mosquitoes15. Although very effective, this strain may be sub-optimal for 
drug screening; introduction of the human dihydrofolate reductase (hDHFR) selection marker during integration 
of the GFP-Luc expression cassette renders it resistant to antifolates16 and makes it necessary to maintain expo-
sure to antifolate compound WR99210 during parasite culture to prevent reversion to wild-type (WT), possibly 
modifying its response to other inhibitors by affecting parasite metabolism. Here we report the development of a 
parasite line that constitutively expresses GFP-Luc and is free of limiting selection markers, for use in an efficient, 
dissection-free SMFA screen. Our approach used frozen mosquitoes and machine homogenisation in a 96-well 
format to improve the efficiency of indiscriminate drug screening. After validation and comparison of luciferase 
expression with microscopy based oocyst counts we used our luminescent SMFA to screen 47 marketed and exper-
imental antimalarials and compared the results with data from the gametocytocidal lactate dehydrogenase (pLDH) 
activity assay and Pfs25 AlphaLISA assay. Furthermore, the luciferase screen was used to evaluate the TRA of 18 
compounds selected from the Medicines for Malaria Venture (MMV) malaria box specifically for their potential 
activity as gametocytocidals. In this final screen, gametocytocidal or permanent inhibitory activity was confirmed 
by incubating gametocytes with compounds before ‘washing out’ the compound prior to mosquito feeding, while 
specific activity against the parasite stages emerging in the mosquito gut was confirmed by adding compounds to 
the gametocyte culture immediately prior to mosquito feeding. These assays identified novel transmission block-
ing small molecules and provide new insight into the predictive value of in vitro metabolic and gamete formation 
inhibition assays, showing they can miss potent compounds, and highlighting the advantages of the gold-standard 
SMFA for screening transmission blocking compounds. Importantly, our more scalable luciferase based read-out 
increases throughput of the assay and makes compound screening with the SMFA less resource intensive than 
when performed with microscopy.
Results
Generation of a GFP-Luc expressing parasite line free of selection markers. To allow unrestrained 
evaluation of new compounds we developed a new parasite line, free of drug selection markers (full title: NF54-
∆Pf47-5′ hsp70-GFP-Luc; hereafter: NF54-HGL), that stably expresses a GFP-Luciferase fusion protein under 
control of the constitutive P. falciparum hsp70 promoter (Fig. 1A,B).
To confirm the proposed effect of removal of the hDHFR selection marker on antifolate sensitivity, we compared 
sensitivity of wildtype NF54, intermediate clone NF54-HGL-hDHFR (created prior to FLP recombinase-mediated 
excision of the hDHFR maker) and NF54-HGL asexual blood stage parasites to dihydroartemisinin (DHA), chloro-
quine, and two antifolate drugs: WR99210 and Pyrimethamine. The half maximal inhibitory concentration (IC50) 
for DHA and chloroquine are comparable for all three parasite lines. As predicted, presence of the hDHFR selection 
marker in NF54-HGL-hDHFR renders this parasite resistant to WR99210 and Pyrimethamine. Excision of the 
hDHFR open reading frame effectively restores sensitivity to these antifolates for NF54-HGL (Fig. 1D–G). Since 
pLDH is a stable enzyme and antifolates have relatively slow parasite killing kinetics, the inhibition by WR99210 
and pyrimethamine did not reach 100% within the timeframe of the assay17.
Assessment of GFP-Luc expression. Analyses of luminescence signals confirmed expression of the 
GFP-Luc protein in asexual blood stage parasites (Fig. 1C). In line with previous reports on different expression 
levels in the various life cycle stages of the parasite18, expression was higher in day 8 gametocytes than in mature 
gametocytes and asexual blood stages. To assess GFP-Luc expression during the parasites development in mos-
quitoes, Anopheles stephensi were fed a blood-meal containing NF54-HGL gametocytes and dissected at various 
time-points post infection (PI) to allow visual inspection of the mosquito midgut. No fluorescence was observed 
during ookinete formation (24 h PI, data not shown), indicating that GFP expression levels may have been under 
the limit for microscopical detection. From day 6 PI GFP positive oocysts were easily observable (Supplementary 
Fig. S1). Luciferase expression was weak during early sporogonic development (2–6 days PI, data not shown), but 
robust signal in low intensity infections (mean oocysts = 1.28, range = 0–7) was detectable from day 7 PI onwards 
(Supplementary Fig. S2). Uninfected negative control mosquitoes showed low levels of luminescence (n = 617; 
mean RLU = 3.2 RLU; standard deviation = 1.9 RLU). Day 8 PI showed a clear separation of positive and negative 
mosquitoes and was chosen for subsequent assessments of infection intensity (i.e. number of oocysts per midgut) 
and prevalence (i.e. percentage of mosquitoes with oocyst stage infection) based on luminescence intensity.
Microscopy and luciferase based assessments of infection and TRA. To confirm that measure-
ments of luciferase activity can replace manual dissection-based oocyst counts, as was previously shown for 
NF54HT-GFP-Luc15, 172 experimental mosquito feeds (hereafter ‘feeds’) were performed using NF54-HGL 
gametocyte culture. From each feed, separate mosquito samples were assayed by standard microscopy and by 
luminescent SMFA (microscopy, n = 2557; luminescence, n = 3570). Thirty-two of these feeds were performed as 
controls allowing for direct comparison of infection intensity and prevalence based on oocyst and luminescence 
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readouts. These were performed either without test compounds (0.1% DMSO, n = 16) or with control compound 
DHA that shows gametocytocidal activity at high concentration (10 μ M DHA, n = 16)13. Mean oocyst counts for 
control feeds were between zero and 29 oocysts (mean 4.9 oocysts), and had a positive linear relationship with 
mean luminescence intensity (R2 = 0.86, p < 0.0001). Similarly, oocyst prevalence was positively associated with 
luminescence based prevalence (R2 = 0.95, p < 0.0001) (Supplementary Fig. S3). Combining all mosquitoes from 
control feeds, prevalence estimates for all mosquitoes from control feeds were 43.33% (208/480) for microscopy, 
and 49.22% (350/711) for luminescence.
To further validate the luminescent SMFA we tested seven compounds from the MMV validation box in full 
dose response in an ‘indirect’ luminescent SMFA format. In the indirect assay, gametocytes were incubated with 
compounds for 24 hours, and mosquitoes were fed a blood-meal containing this gametocyte culture/compound 
mix. Microscopic examination of oocyst densities in midguts and luminescence measurements were performed on 
distinct cohorts of mosquitoes from the same cage. As shown in Fig. 2, all compounds dose-dependently reduced 
oocyst formation and luminescence intensity. Data were fitted to a Hill equation using Maximum Likelihood 
Estimation to find the best fit. The dose response curves fitted on the microscopy and luminescence data aligned 
very well for artemisone, atovaquone, mefloquine, NPC1161B, pyrimethamine and pyronaridine. The curves for 
lumefantrine appeared to be less well aligned due to a distinct dispersion of oocyst counts and RLU values at the 
highest concentration tested. For all other compounds the derived IC50 values differ by no more than 2–3 fold 
when comparing the two read-outs.
The luminescent SMFA identifies compounds with different modes of TRA. Using only lumines-
cence readouts, we screened 47 established antimalarial compounds in the indirect luminescent SMFA format 
at a 5 μ M concentration. Samples of 22–24 mosquitoes were analysed for each compound (n = 46*24; 1*22). The 
results of this rapid screen are shown in Fig. 3A, with TRA (%) calculated using generalised linear mixed models 
(GLMM) from differences in the intensity of infection between test and vehicle (0.1% DMSO) control feeds. 
Figure 1. (A) Schematic of the gene targeting strategy to insert a GFP-Luc reporter gene under control of 
the hsp70 promoter in the pfs47 locus, showing the genomic locus of the wild-type (WT) and gene deletion 
mutants ∆pf47 containing the GFP-luciferase ORF before and after removal of the hdhfr resistance marker. 
P1, P2: primers MWV300 and MWV301, respectively, used for PCR analysis; X (XcmI), N (NcoI): restriction 
sites used for conformation of LR-PCR analysis; pf47: pf47 locus; hrp: histidine rich protein; cam: calmodulin; 
hsp: heat shock protein; hdhfr: human dihydrodrofolate reductase coding region; GFP-Luc: GFP-luciferase 
fusion protein; fcu: cytosine deaminase/uracil phosphoribosyl transferase; pbdt: P. berghei dhfr transcription 
termination region; kb: kilo basepairs. (B) Verification of the integration site by PCR and restriction digestion. 
Genomic DNA fragments from the parental NF54 strain (WT), intermediate transgene NF54-HGL-hDHFR 
and final transgene NF54-HGL were amplified by PCR using primers MWV300 and MWV301 (P1 and P2) and 
analysed by DNA gel electrophoresis. Where indicated, the PCR fragment was subjected to restriction digestion 
with XcmI/NcoI (X/N) (C) Luminescence intensity (relative light units, RLU) as a function of cell number. The 
figure shows a comparison between uninfected red blood cells (RBC), immature gametocytes (Day 8 GCT), 
mature gametocytes (Day 14 GCT) and asexual blood stage parasites. (D–G) FLP-FRT mediated excision of 
the selection marker restores sensitivity to antifolates. Drug sensitivity analysis of WT, ∆Pf47GFP-luc-hdhfr 
and ∆Pf47GFP-luc to DHA (D), Chloroquine (E), Pyrimethamine (F), and WR99210 (G) in a dose dependent 
asexual growth inhibition assay using pLDH enzyme activity as a readout. Depicted data represents a triplicate 
measurement and was normalized to the MIN (10 μ M DHA) and MAX (0.1% DMSO) controls. Error bars 
indicate standard deviations.
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Thirty-four compounds had statistically significant TRA based on reductions in luminescence intensity; 21/34 
with ≥ 80% TRA15.
To provide more information on the mechanism of active compounds, all compounds showing ≥ 80% TRA 
on the intensity scale in the indirect assay were re-tested, this time adding compounds to the blood/gametocyte 
culture mix immediately prior to mosquito feeding (hereafter, the ‘direct’ assay variant). Fourteen compounds 
had > 80% TRA in the indirect assay but not in the direct assay, suggesting the absence of strong activity against 
Figure 2. Standard Membrane Feeding Experiments for 7 compounds from the MMV validation box, 
assessed both by microscopy and luciferase assay. All compounds were tested in nine dilutions in duplicate. 
The figure shows oocyst counts in individual mosquitoes and relative light units (RLU) from a distinct cohort 
of mosquitoes from the same cage. The table shows IC50 values and cognate 95% confidence intervals (CI) 
determined from fitting the data to a logistic regression model by Maximum Likelihood Estimation. NA: 
confidence interval not computed as the model did not converge.
Figure 3. (A) Single concentration (5 μ M) rapid luminescent SMFA screen of 47 compound from MMV 
validation box, assessed with the indirect and direct assay variants. TRA% was calculated from relative 
differences between test and control feed luminescence intensity. Error bars indicate 95% confidence intervals. 
(B) Heat map comparing the SMFA data to published data from pLDH and Pfs25-based gametocyte viability 
assays. The numbers indicate percentage inhibition at a compound concentration of 5 μ M. A color scale from 
green to red indicates low to high inhibition.
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the parasite life stages occurring in the mosquito gut. Amino alcohol halofantrine, antifolates P218, pyrimethamine 
and chlorproguanil, synthetic dye methylene blue, BC1 inhibitor atovaquone, and protein synthesis inhibitor 
cycloheximide had comparable TRA in the indirect and direct SMFA formats, indicating activity against mosquito 
stage parasites, but not excluding the possibility of concurrent gametocytocidal action.
The luminescent SMFA identifies compounds with TRA that are missed by gametocyte and 
gametogenesis assays. The results of the indirect and direct assays were compared with previously described 
data13 showing the effect of the same 47 compounds at 5 μ M in a gametocyte viability assay with pLDH readout, and 
a homogeneous immunoassay detecting the Pfs25 antigen on emerging female gametes (Fig. 3B). At a threshold 
of ≥ 80% inhibition, the pLDH and gametogenesis assays identified 6/47 and 13/47 compounds respectively as 
having gametocytocidal activity. The activity of all but one of the six compounds identified by the pLDH assay 
(napthoquine) was confirmed by the gametogenesis assay, while all hits from either viability assay were confirmed 
in the indirect luminescent SMFA. However, high TRA was observed for a number of compounds where the inhi-
bition assays showed low activity, indicating that some compounds had activity only identifiable with transmission 
as the definitive readout. Total false negative rates for the pLDH and gametogenesis assays were 32% (15/47) 
and 17% (8/47), respectively. Excluding compounds that blocked transmission in the direct luminescent SMFA, 
which we presumed to have activity downstream of the gametocyte, the SMFA still identified a larger number of 
transmission-blocking compounds than either gametocytocidal assay, with false negativity rates of 25% (10/40) in 
the pLDH assay and 10% (4/40) in the gametogenesis assay. This is not surprising since the SMFA covesr a higher 
biological content than either of the other two methodologies.
Identification of novel transmission-blocking small molecules. In recent years, a number of gameto-
cyte assays have been developed that attempt to predict gametocyte viability and infectivity based on metabolic 
activity, reporter gene expression, or changes in cell shape or antigen expression11–13,19–26. In an effort coordinated 
by the Bill & Melinda Gates Foundation and the Medicines for Malaria Venture (MMV), a number of these and 
additional novel assays selected a subset of compounds from the MMV Malaria box as potentially transmission 
blocking. All of these molecules kill asexual blood stage parasites with submicromolar IC50s (Table 1). Here, we 
evaluated 18 of these selected compounds in full dose-response experiments using the luminescent SMFA. In order 
to confirm a gametocyte-based mechanism of action, compounds were washed out following incubation with stage 
V gametocytes to prevent activity against parasite stages emerging in the mosquito midgut. Effectiveness of the 
washing step was tested by evaluating the activity of pyrimethamine, which has potent activity against the parasite 
stages that develop in the mosquito midgut (Fig. 2) but not against gametocytes27. Indeed, washing a culture of 
gametocytes exposed to pyrimethamine restored subsequent oocyst development in the mosquito, confirming 
that this format of the assay is likely restricted to the analyses of gametocytocidal modes of actions (Supplementary 
Fig. S4). This might however be different for more lipophilic drugs, which might be washed out with less efficiency. 
Sixteen out of the 18 Malaria box compounds tested in this wash-out mode of the SMFA dose-dependently reduced 
oocyst development in the mosquito midgut (Fig. 4). Compounds MMV665941, MMV667491, MMV019918 and 
MMV665827 were among the most potent transmission-reducing molecules, with IC50 values of 0.04, 0.06, 0.07 
and 0.1 μ M, respectively. To reveal whether these compounds act against the parasite stages that develop in the 
mosquito midgut on top of their gametocytocidal activity, all compounds were tested in the direct assay variant at 
the same maximum concentration as in the wash-out assay (10 μ M), confirming that 10/18 compounds significantly 
reduced mosquito oocyst intensity Compounds MMV020492 and MMV665882 that did not show gametocytocidal 
activity were equally inactive in the direct SMFA. To further address the mechanism of action of compounds with 
functional TRA, the SMFA data were compared to data from published studies that addressed different aspects 
of gametocyte biology (Table 1). MMV019918 was the only compound consistently showing activity across the 
different assay formats, although IC50 values ranged from 0.07 μ M to 0.9 μ M, with large differences between the 
two assays that interrogated the ability of a gametocyte to undergo exflagellation. Conversely, MMV007116 and 
MMV665827 showed potent activity in the SMFA but very low activity in the published gametocyte assays, with 
the exception of a luciferase reporter assay that revealed the effect of these compounds on gametocyte viability. In 
general, the luminescent SMFA identified more compounds with functional TRA than predicted by each of the 
individual published gametocyte assay formats.
Discussion
The firefly luciferase expressing parasite line NF54-HGL enables the SMFA to be performed for indiscriminate 
compound screening with a semi-automated luciferase based read-out. The results of the current study demon-
strate the versatility of the SMFA for screening compounds with activity against different transmission stages of the 
malaria parasite, and validate the luminescent assay format in combination with microtiter plate-based processing 
of mosquitoes for improving the efficiency of the biological gold-standard for assessing Plasmodium transmission 
in controlled experiments.
We presented a screening pipeline for the SMFA that allowed us to investigate drug mechanism of action 
while retaining transmission as the assay end-point. The indirect assay, in which compounds were incubated with 
gametocytes for 24 hours prior to mosquito feeding, represents the simplest and most sensitive screen and the first 
step in the pipeline for screening large compound libraries. The direct assay, in which the compound is added at 
the moment the gametocyte activates to form a gamete, interrogates compound action in the mosquito midgut. 
Pharmacokinetics in the mosquito are largely unknown, but detoxifying enzymes may limit the compound’s 
action in the midgut, restricting the direct SMFA to monitoring effects on gametogenesis, ookinete formation 
and perhaps early sporogony28. Lastly, the wash-out format of the SMFA addresses a mode of action that is likely 
restricted to the gametocyte. High-throughput screening is impossible with the SMFA, but the luminescent SMFA 
represents a significant improvement in the techniques scalability. The replacement of direct oocyst counts with 
www.nature.com/scientificreports/
6Scientific RepoRts | 5:18704 | DOI: 10.1038/srep18704
luciferase measurements from homogenised mosquitoes in the SMFA was described previously15 for parasite line 
NF54HT-GFP-luc16, but aspects of the methodology described here differ. The current reporter parasite is devoid 
of the DHFR selection marker, allowing for precise description of the effects of antifolates including pyrimeth-
amine on oocyst development, and expediting the evaluation of a wide variety of compound libraries. Mosquito 
sample sizes were limited to increase throughput, and freezing mosquitoes prior to further processing increased 
flexibility of laboratory operations. Furthermore, semi-automated processing of mosquitoes significantly reduced 
the time needed for assessment of infection status. In all, the luminescent format for individual mosquitoes reduces 
hands-on time 2-fold in comparison with the microscopical readout, which is a tremendous step up from a pre-
viously published ‘industrialized’ SMFA format29. For even further increased throughput, screening in the lumi-
nescent SMFA may be performed by pooling larger numbers of mosquitoes, achieving an approximate four-fold 
increase in throughput over the standard microscopical readout if only infection intensity is the desired output15.
Our data from a large number of infections indicate that oocyst intensity is a simple linear function of lumines-
cence intensity. This is in keeping with our previous work that showed a linear relationship between oocyst counts 
and luminescence intensity, using a different promoter to drive expression of the reporter gene15. Oocysts are an 
intermediate parasite life-stage which even when developing concurrently in a host mosquito may differ in size 
and sporozoite content30–32. Whereas microscopy produces discrete data, luminescence measurements provide 
continuous data that reflect actual numbers of developing sporozoites, which may be more directly relatable to 
mosquito infectivity, for which oocyst counts are an accepted proxy. An added advantage of the luminescent assay 
is that it is less subjective than microscopy based assessments of oocyst numbers. We cannot exclude the possibility 
that in heavily infected mosquitoes, with higher oocyst intensities than those reported here, nutrient and space 
competition may lead to lower per capita sporozoite production, resulting in a non-linear relationship between 
luminescence and oocyst intensity and lower luminescence based TRA estimates than would be determined from 
oocyst number alone. Though we advise caution in extrapolating actual oocyst number from luminescence values, 
we believe luminescence based TRA estimates may be more accurate than those made using oocyst data.
In the direct mode of the SMFA the compound remains present in the bloodmeal, and there is a remote possi-
bility that it interferes with activity of the luciferase reporter rather than with oocyst development. We have been 
unable to investigate the potential effect of compounds interacting with hsp70 expression, as has been observed in 
other eukaryotes33, or the possibility that compounds may directly inhibit luciferase protein after its production34. 
Compound
washout SMFA
direct 
SMFA published gametocyte assay data
asexual 
blood 
stage†
IC50 μM (95% 
CI) slope (95% CI)
% inh. 
10 μM
exflagellation12 
(imaging) 
IC50 μM (% 
inh. 1 μM)
Pfs2512 
IC50 μM (% 
inh. 1 μM)
alamarBlue24 
IC50 μM (% 
inh. 5 μM)
imaging25 
IC50 μM 
(% inh. 
5 μM)
exflagellation26 
(SYBR green) 
IC50 μM (% 
inh. 10 μM)
IC50 
(μM)
MMV000248 1.64 (1.26 − 2.13) -2.44 (-3.07 − -1.81) 48.76* NA (-66%) NA (8%) 0.31 1.1 NA (95%) 0.72
MMV000442 0.59 (.35 − 1.01) -1.18 (-1.58 − -0.78) 5.50 NA (-12%) NA (6%) NA (72%) 0.92 (55%) NA (59%) 0.36
MMV000448 1.18 (1.07− 1.31) -11.63 (-15.91 − -7.34) 97.93* 0.25 4.02 1 0.71 5.4 0.23
MMV007116 0.11 (.06 − .19) -1.62 (-2.15 − -1.08) 99.22* 20.75 NA (10%) NA (40%) 0.26 NA (67%) 0.35
MMV011438 8.58 (7.95 − 9.26) -8.47 (-12.62 − -4.32) -3.29 NA (-77%) NA (-31%) 0.82 1.13 NA (69%) 0.32
MMV019266 1.29 (1.21 − 1.38) -9.38 (-12.41 − -6.35) 7.07 NA (31%) NA (-11%) 0.31 0.33 NA (81%) 0.62
MMV019881 1.17 (. − .) -15.81 (. − .) 88.15* NA (57%) NA (-7%) NA (76%) NA (32%) 5.5 0.65
MMV019918 0.07 (.04 − .13) -1.36 (-1.80 − -0.93) 88.55* 0.07 0.52 0.32 0.7 0.9 0.79
MMV020492 ND ND -16.63 NA (36%) NA (-12%) NA (70%) NA (-5%) NA (59%) 0.03
MMV396797 3.62 (.87 − 15.18) -4.10 (-9.87 − 1.67) -16.44 NA (-14%) NA (-17%) NA (90%) 0.01 8.8 0.48
MMV665827 0.10 (.06 −.15) -2.23 (-3.05 − -1.42) 98.25* 16.55 NA (-15%) NA (41%) 0.34 NA (66%) 0.12
MMV665882 ND ND 4.92 NA (-12%) NA (-48%) NA (92%) 0.07 NA (75%) 0.47
MMV665941 0.04 (. − .) - 10.29 (. − .) 99.84* 0.42 0.3 NA (86%) 0.32 1.8 0.26
MMV665971 3.22 (1.45 − 7.15) - 1.50 (- 2.57 − - 0.44) -7.04 NA (– 29%) NA (– 13%) NA (73%) 0.23 NA (61%) 0.49
MMV665980 1.76 (1.57 − 1.96) - 11.52 (- 25.29 − 2.24) 64.17* 8.07 NA (74%) NA (27%) NA (91%) NA (76%) 0.21
MMV666021 1.25 (1.17 − 1.34) - 13.30 (- 17.32 − - 9.28) 94.02* NA (30%) NA (– 20%) NA (58%) 0.61 NA (68%) 0.09
MMV666125 1.40 (1.11 − 1.76) - 2.86 (- 3.97 − - 1.76) - 24.69 NA (– 3%) NA (– 17%) 0.48 0.75 NA (74%) 0.38
MMV667491 0.06 (.03 − .11) - 0.61 (- 0.73 − - 0.50) 89.05* 0.09 0.18 NA (91%) 1.06 4.5 1.23
Table 1.  Compound activity as determined in the luminescent SMFA compared to activities reported by 
published gametocyte viability assays and asexual replication assays. The table shows IC50 values where 
available (NA: not available) or the percentage inhibition at the highest concentration tested, as indicated in 
the header row. IC50 data for the exflagellation (imaging) and Pfs25 assays were generated in a washout format, 
whereas percentage inhibition values represent data from a continued exposure experiment12. For SMFA data, 
95% confidence intervals are indicated between brackets where possible. For MMV019881, and MMV665941 
the model did not converge. Asterisks (*) indicate statistically significant inhibition (p < 0.05) in the direct 
SMFA. † The last column shows activity against asexual blood stages of P. falciparum strain 3D7 as deposited at 
the ChEMBL repository under accession number CHEMBL2028071. ND: no dose response relationship was 
detected in the data.
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We consider both events highly unlikely to affect the luciferase readout in the current SMFA format, as compounds 
are at latest added to the mosquito bloodmeal 8 days before luminescence measurements. Furthermore, analyses 
of a subset of the MMV malaria box compounds in a luciferase inhibition assay did not reveal inhibitory activity 
at the concentrations that reduce oocyst development22. The possibility that some compounds may effect mosquito 
metabolism, and by proxy parasite developmental success, can also not be excluded. Readouts based on oocyst 
number may be insensitive to such subtle effects, while the more quantitative luminescence readout may not be. 
Additional experiments will be required to elucidate the interaction of mosquito and parasite fitness in relation 
to compound exposure.
Figure 4. Dose response experiments for 18 compounds from the MMV malaria box, assessed in the 
luminescent SMFA in a wash-out assay variant. All compounds were tested in duplicate in two independent 
experiments. The figure shows oocyst intensities relative to vehicle control (0.1% DMSO) as a function of 
concentration for the compounds indicated at the top of the panels.
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Apart from oocyst intensity, oocyst prevalence (the proportion of mosquitoes that develop an oocyst-stage 
infection), is an important parameter determining malaria transmission. Whereas inter-experimental variation 
in control mosquito oocyst burden has no effect on TRA expressed as a reduction in oocyst intensity, it heavily 
influences the outcome based on a reduction in oocyst prevalence35. Since our experiments comprised a large set 
of experimental infections that each showed a distinct distribution of oocyst densities we have, therefore, limited 
our analyses to a comparison of compound effects on oocyst intensity, as this is the only parameter that is directly 
comparable between experiments. Nevertheless, a complete assessment of the transmission blocking potential of 
an antimalarial would require a description of the effects on infection prevalence, preferable at infection intensities 
that mimic those observed in naturally infected mosquitoes36. An experimental and computational strategy to 
achieve such an assessment has been implemented in our laboratory and will be described elsewhere.
Compounds reducing malaria parasite transmission to mosquitoes may kill gametocytes directly (gametocy-
tocidal activity), irreversibly impair the parasites ability to develop once ingested by the mosquito, or else inhibit 
gametocyte developmental viability only while drug pressure is maintained in the mosquito environment12. Because 
mature gametocytes persist at low densities for several weeks after ACT treatment6, and because submicroscopic 
gametocyte densities may be highly transmissible37,38, efforts to develop transmission-reducing compounds are 
focused on identifying activity against mature gametocytes39. In vitro assays based on markers of metabolic activity 
(pLDH13,19, Alamar Blue reduction20) or reporter genes21,22,40 can be used to assess the effects of gametocytocidal 
compounds but may overlook compounds that manifest their action downstream of the gametocyte. Gametocyte 
infectivity may be assessed in greater detail with gamete formation assays, which can include gametocyte washing 
steps to discriminate between reversible and irreversible compound activity12,13,23. In vitro ookinete formation 
assays can also be used to identify compounds whose presence in the mosquito blood meal inhibits parasite 
fertilisation41, but these assays cannot exclude the possibility of compounds reducing ookinete viability or oocyst 
formation. Assays measuring the viability or development of gametocytes without mosquito feeding are compar-
atively inexpensive and highly scalable, so will continue to be required as a prioritization step in the screening 
pipeline for transmission blocking drugs. The data presented here indicate, however, that increased throughput of 
in vitro gametocyte assays goes at the cost of a considerable number of false negatives. Importantly, as no in vitro 
assay or combination of assays is able to fully interrogate the effect of compounds on all parasite developmental 
stages exposed to test compounds, our results underline that the SMFA remains the gold standard assessment of 
gametocyte infectivity. Our indirect screen of a varied set of 47 antimalarials identified compounds preventing 
mosquito infection by mechanisms targeting any stage of the parasites sexual development or early sporogony. 
Assays based on parasite metabolic processes (pLDH) and on the expression of female gamete upregulated protein 
Pfs25 cumulatively failed to identify seven compounds which, incubated with cultured gametocytes (NF54-HGL) 
in the same concentration, caused marked reductions in oocyst stage productivity as assessed by the luminescent 
SMFA. Though we anticipated identifying compounds with additional activity downstream of gamete formation 
in the SMFA, the results of the direct assay indicate that the pLDH and gamete formation assays failed to identify 
compounds with effects restricted to the gametocyte; three of the seven false negatives had no activity on mosquito 
stage parasites in the direct SMFA format. The effect of the remaining four compounds may rely on a sporontocidal 
rather than a gametocytocidal activity. In keeping with previous reports of their sporontocidal activity (reviewed 
in Butcher42), pyrimethamine and atovaquone blocked oocyst development but were not active in the pLDH and 
gamete formation assays. Atovaquone has demonstrated a long-lasting transmission-blocking effect in ex vivo 
studies with sera from drug-treated volunteers43, but the effect on transmission in malaria endemic settings has 
not been described in detail. The sporontocidal effect of pyrimethamine most likely represents a class effect of 
dihydrofolate reductase (DHFR) inhibitors, as it was also observed for P218 and chlorproguanil. Proguanil was 
understandably not active in the SMFA as only its active metabolite cycloguanil binds to DHFR44.
Analyses of eighteen compounds from the MMV malaria box revealed sixteen compounds with functional 
TRA that were not necessarily identified by individual gametocyte based assay formats12,24–26. These 18 com-
pounds were flagged as potential transmission blockers by a joint effort coordinated by the Bill and Melinda Gates 
Foundation and the Medicines for Malaria Venture under the ‘Gametocyte Assays for Plasmodium falciparum’ 
program. Under this program, five consortia consisting of two to five malaria laboratories each screened the MMV 
malaria box in a variety of gametocyte-based assays. All consortia proposed a shortlist of active molecules for fur-
ther evaluation in the SMFA. The final selection of 18 molecules, governed by MMV, was then based on potency, 
diversity in chemical scaffolds and presumed tractability. As these compounds were expected to act at the level 
of the gametocyte, we applied a wash-out format to restrict the analysis to the sexual blood stage of the parasite 
when testing these compounds in the luminescent SMFA. For the 18 compounds subjected to this more rigorous 
investigation, 16 were able to reduce onward oocyst development in the mosquito with potencies ranging from 8.6 
to 0.04 μ M. The luminescent SMFA did not reveal TRA for MMV020492, which is in line with its lack of activity in 
published gametocyte assays. Equally inactive in the SMFA, MMV020492 showed a lack of activity in most pub-
lished gametocyte assays, with the exception of a luciferase assay that indicated an IC50 of 62 nM. Overall, from a 
qualitative perspective the luciferase assay showed the best agreement with the SMFA, as it identified 14 out of the 
16 compounds with functional TRA. Assays that interrogate the ability of a gametocyte to form a male or female 
gamete did not identify MMV000442 as a potential transmission reducing compound12, whereas it showed an 
IC50 of 590 nM in the SMFA. This indicates that gametocyte infectivity is defined by a greater set of functions than 
described by its sole ability to form a gamete. Quantitatively, neither of the published gametocyte assays correlated 
particularly well with the SMFA, as IC50 values could vary up to 180-fold (e.g. MMV007116 SMFA vs gametocyte 
exflagellation). In addition, the rank order of compounds appeared to be different for all assays. This implies that 
in vitro gametocyte assays provide limited guidance for studies aimed at an understanding of dose in relationship 
to efficacy. Although mouse models have been proposed to determine the efficacious dose for blockage of malaria 
transmission, these are restricted to P. berghei parasites and have limited value for predicting efficacy on human 
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malaria. In addition, P. berghei infection intensities are much higher than P. falciparum infection intensities, which 
leads to an underestimation of TRA when estimated from differences in infection prevalence35,45.
Our studies identified four compounds from the malaria box with IC50 values below 100 nM in the luminescent 
SMFA (Fig. 5). Compounds MMV665827, MMV665941, and MMV667491 lack structural properties that meet 
Lipinski’s rule of five that predicts oral absorption of a candidate drug46. Therefore, these compounds are considered 
tool compounds rather than drug-like molecules47. Nevertheless, these compounds may have value in the identifi-
cation of mechanisms underlying transmission-blocking activity, which remain poorly understood. Importantly, 
these molecules have activity against asexual blood stage parasites, which opens the possibility of selecting drug 
resistant mutants followed by whole genome sequencing. This strategy has been successfully employed in the 
identification of PI4K, and eEF2 and confirmation of DHODH as bonafide drug targets48–50. From the group of 
compounds with potent transmission blocking activity, MMV19918 appears to qualify as a drug-like molecule and 
may, besides serving as a tool in unravelling mechanism of action, act as a starting point for further optimization. 
This compound appeared 10-fold more active in the SMFA as in assays interrogating activity against the asexual 
blood stages. Such a transmission-selective profile was also observed for MMV665941 and MMV667491. To the 
best of our knowledge these are the first molecules described to date that show selectivity towards the transmis-
sion stages of the parasite. Recently, the malaria drug development pipeline was enriched with molecules like 
OZ439, DSM265 and DDD107498, which unlike the majority of marketed antimalarials have activity against the 
transmission stages of the parasite51. However, for all these molecules this activity is at par or less potent than the 
activity observed against asexual blood stage parasites13,49,50,52. The observation of a transmission-selective profile 
in the study presented here suggests a novel mechanism of action outside the range of targets described to date. 
In view of the need for molecules that address a target candidate profile for prevention of transmission53, these 
mechanisms and the molecules identified here warrant further investigation.
Conclusion
The results of the current study demonstrate the sensitivity and flexibility of the SMFA for determining the effect of 
small molecules on P. falciparum gametocyte transmission to mosquitoes, while validating a method that increases 
the assays scalability and ease of use. Comparison to gametocyte inhibition assays indicates that parasite develop-
ment in the mosquito may be required to ensure assay sensitivity to transmission-blocking small molecules. Of the 
18 compounds selected in this analysis based on the results of previous gametocyte assays, our data indicate that 
3 compounds have greater activity on transmission stage parasites than asexual stage parasites. These molecules 
may be of particular interest for further drug discovery and elucidation of novel drug targets.
Methods
Parasites and culture. Asexual blood stages of all P. falciparum parasite lines were cultured in RPMI 1640 
medium supplemented with 367 μ M hypoxanthine, 25 mM HEPES, 25 mM sodium bicarbonate and 10% human 
type A serum, in a semi-automated system under standard conditions and induction of gametocyte production 
was performed as previously described54–56.
Generation of NF54-HGL-hDHFR and NF54-HGL parasite lines. The GFP::LUC fusion protein under 
control of the hsp70 promoter was stably integrated into the genome of asexual stage NF54 (WT) parasites at the 
pfs47 locus (PF13_0248) by standard double crossover recombination and positive/negative selection57–59. The 
targeting plasmid was based on the gene deletion construct pHHT-FRT-Pf5236 described previously60. The p52 
3′ target region in pHHT-FRT-Pf5236 was replaced by the 3′ pfs47 target region amplified by PCR using primers 
MWV257 and MWV259 (primer sequences in supplemental Table S1) and introduced in the plasmid by MluI/
SacII restriction digestion and ligation. The 5′ p52 region was replaced with the 5′ pfs47 target region amplified by 
PCR using primers MWV262 and MWV267 and introduced in the plasmid by XmaI/NarI restriction digestion and 
ligation. A reporter gene cassette was constructed by subcloning a GFP::LUC fragment from plasmid PL106361 in 
pCR2.1-BLUNTII-TOPO after AflII/XbaI restriction digestion. An AgeI restriction site was introduced immedi-
ately upstream of the start codon by introducing a PCR fragment amplified with primers MWV252 and MWV253 
through KpnI/HpaI restriction digestion and ligation. The promoter region of the hsp70 gene (PF3D7_0818900) 
was placed upstream of GFP through sacII/AgeI restriction digestion and ligation after amplification with primers 
MWV198 and MWV200 and subcloning in pEGFP-N1 (Clontech laboratories, Mountain view, CA) through 
BamHI/SacII digestion and ligation. The 3′ transcription termination region from the hsp86 gene (PF3D7_0708400) 
was introduced following PCR amplification using primers MWV268 and MWV271 and XbaI/ApaI restriction 
Figure 5. Potent transmission-blocking molecules. The depicted compounds showed an IC50 < 100 nM in 
the luminescent SMFA.
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digestion and ligation. Finally the reporter cassette was introduced in the gene targeting plasmid by KpnI/NgoMIV 
restriction digestion and ligation yielding plasmid pMV163.
Pfs47 target regions, 5′ hsp70 and 3′ hsp86 fragments were amplified by PCR amplification (Phusion, Finnzymes) 
from genomic P. falciparum DNA (NF54 strain) and all PCR fragments were sequenced after TOPO TA (Invitrogen) 
sub-cloning.
Transfection of wild type NF54 asexual parasites with DNA construct pMV163 was performed as described 
previously59 using a Electro Cell Manipulator 600 (BTX, Holliston, USA) Double crossover mutants were selected 
by positive and negative selection as described57, yielding parasite line NF54-HGL-hDHFR. Cloning of transgenic 
parasites was performed by limiting dilution in 96-well plates as described62. Parasites in positive wells were trans-
ferred to the semi-automated culture system and cultured for further phenotype and genotype analyses.
Removal of the hdhfr selection marker was next performed by transfection of the mutants with construct 
pMV-FLPe and selection on blasticidin60,63, resulting in parasite line NF54-HGL. Integrity of the transgenes was 
analysed by PCR using primers MWV300 and MWV301 and XcmI/NcoI restriction digestion.
To confirm functional FRT-mediated excision of the hDHFR selection marker, sensitivity to anti-folates and a 
number of non-folate reference compounds were performed on NF54 (WT), NF54-HGL-hDHFR, and NF54-HGL 
using a modified pLDH assay. Briefly, non-synchronised asexual parasites (~50% ring stages, 25% trophozoites and 
25% schizonts) were seeded at a density of 0.5% parasitaemia in 3% haematocrit in a black 96-well plate in 50 μ l of 
culture medium, with 50 μ l of diluted test compound. Following a 72 hour incubation at 37 °C, 98% humidity, 93% 
N2, 4% CO2 and 3% O2, the increase in parasitaemia was assessed using the modified pLDH assay as described 
previously13. Assays were performed in triplicate (three serial dilutions for each compound) and all plates included 
triplicate controls to assess minimum (MIN control, 1 μ M DHA) and maximum (MAX control, 0.1% DMSO) 
signal. To compare the three different strains data were normalized and expressed as the percentage reduction in 
replication relative to the blocking and non-blocking controls.
GFP fluorescence analysis. The midguts of mosquitoes fed previously with NF54-HGL gametocyte culture 
were mounted on glass slides in a droplet of PBS, and GFP expression was visualized and photographed on a Leica 
fluorescence microscope with digital camera.
Standard Membrane Feeding Assays. In the ‘indirect’ mode of the SMFA, gametocytes were pre-incubated 
with test and control compounds prior to mosquito feeding. To this end, compounds were dissolved in DMSO to 
achieve a stock solution of 10 mM that was serially diluted in DMSO to achieve concentrations 1000-fold above 
the final test concentration. Subsequently, 10 μ l of diluted compound in DMSO was added to 990 μ l pre-warmed 
RPMI 1640 medium supplemented with 367 μ M hypoxanthine, 25 mM HEPES and 25 mM NaHCO3 (‘incomplete 
medium’). 40 μ l of this intermediate dilution was added to 360 μ l of parasite culture and incubated for 24 hrs at 
37 °C in Eppendorf tubes, resulting in 0.1% final DMSO concentration. Hereafter, 300 μ l of the gametocyte cul-
ture/compound mix was added to 180 μ l of packed red blood cells and centrifuged for 20 seconds at 10,000 × g. 
After carefully aspirating the supernatant, 200 μ l of human serum type A was added to the pellet. Finally, 300 μ l 
of this mix was immediately injected into an individual membrane covered minifeeder, where 50 female A. ste-
phensi mosquitoes were allowed to feed for 10 minutes. In the ‘wash-out’ mode of the SMFA, compounds were 
washed out following preincubation by adding 14 ml incomplete medium supplemented with 10% human type A 
serum (‘complete medium’) to the gametocyte suspension, followed by centrifugation (2000 × g) for 7 minutes. The 
supernatant was removed and the gametocytes were washed again with 14 ml of complete medium. The pellet was 
resuspended in 300 μ l of complete medium and combined with 180 μ l packed red blood cells. All media used for 
washing were prewarmed to 37 °C and the subsequent preparation of the blood meal was as described above. For 
the ‘direct’ mode of the SMFA, 300 μ l parasite culture was added to 180 μ l red blood cells, centrifuged for 20 sec-
onds at 10,000 g and the supernatant was carefully aspirated. Meanwhile, 10 μ l of compound diluted in incomplete 
medium was added to 490 μ l human serum type A (0.1% DMSO final). 200 μ l of this human serum/compound 
mix was added to the gametocyte culture pellet, which was subsequently used for the SMFA as described above. 
For dose response analyses, compounds were diluted in DMSO with subsequent dilution in culture medium to a 
final DMSO concentration of 0.1%. Controls included vehicle (0.1% DMSO) and DHA at its approximate IC90 
(10 μ M). For all assay types, unfed and partially fed mosquitoes were removed from the cage after feeding, and fed 
mosquitoes were maintained at 26 °C, 80% humidity. Mosquitoes were either dissected and examined for midgut 
oocysts on day 6–8 PI as described64,65, or processed in the luciferase activity assay on day 8 PI.
Mosquito processing and luciferase assay. To enhance flexibility, and to ensure that individual mosqui-
toes were safely and efficiently transferred from feeding cages to 96-well plates for homogenisation, mosquitoes 
were immobilised at day 8 PI and stored at − 20 °C in sealed 15 ml falcon tubes for at least 24 hours and up to 2 
weeks, before being processed in the luciferase assay. Upon removal from storage at − 20 °C mosquitoes were 
thawed and individually added to wells in shallow 96-well plates containing 60 μ l PBS with Complete protease 
inhibitor cocktail according to the instructions of the manufacturer (Roche, Switzerland), and 0.2 gram of 1.0 mm 
diameter zirconia beads (Lab Services BV). Plates were next placed in a Mini-Beadbeater-96 (Biospec, Bartlesville, 
OK) and rocked for 2*15 seconds, with 1–2 minutes on ice between rounds of homogenisation. Based on visual 
inspection, this procedure achieved a homogenate consistency in line with that achievable using a hand-held pestle 
rotator as described previously15. For the individual mosquitoes 45 μ l of homogenised material was transferred to 
wells in a Krystal 2000 black & white 96-well plate (Porvair, United Kingdom). Next 45 μ l of Bright-Glo luciferase 
assay substrate (Promega, Madison, WI) was added to each well using a Cybi Selma dispensing station (Cybio, 
Germany) and the plate was incubated for 3 minutes at room temperature. Luciferase activity was measured using 
a Synergy 2 multi-purpose plate reader (Biotek, Winooski, VT). Background was determined by measuring unin-
fected mosquitoes that had undergone the same treatment.
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pLDH and Pfs25 assays. Assays were performed as described previously13.
Data analysis. Statistical analysis was conducted using R (Foundation for Statistical Computing, Vienna, 
Austria), STATA 12 (StataCorp., TX, USA) and GraphPad Prism 5.0 (GraphPad Software Inc., CA, USA).
All comparisons of microscopy and luciferase outcomes were conducted with separate groups of mosquitoes 
for each measure sampled from the same feeds. Comparisons between oocyst and luminescence based measures of 
mosquito infection prevalence were made with Chi-squared tests with Bonferonni correction. Associations between 
oocyst and luminescence intensity were quantified with linear regression. 95% confidence intervals around mean 
luminescence and oocyst intensity data was calculated by bootstrapping (1000 repetitions). Luminescence and 
microscopical TRA estimates were made using generalised linear mixed models (GLMMs)35,66. For assessment of 
infection prevalence, the cut-off for RLU based infection positivity was determined arbitrarily as the mean lumi-
nescence intensity of all uninfected controls plus five standard deviations (12.7 RLU), as described previously15. 
For gametocyte viability and gametogenesis assays, data were expressed as the percentage effect relative to the MIN 
and MAX controls13. For SMFAs, data were expressed relative to the negative (vehicle) controls for oocyst density 
and oocyst prevalence (i.e. the proportion of infected mosquitoes). IC50 values were calculated by applying a 
four-parameter logistic regression model using a Maximum Likelihood Estimation algorithm to find the best fit.
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